NEW YORK (GenomeWeb) – Proteomics International said today it has entered a strategic alliance with CPR Pharma Services focused on clinical trials and related research.

Under the terms of the deal, Proteomics International will acquire 10 percent of CPR's share capital in exchange for 4 million of its shares. This transaction is subject to CPR shareholder approval and is scheduled to take place on March 5, 2018.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.